ABCD1 and cystic fibrosis: The United States Food and Drug Administration-approved drug ivacaftor for the treatment of cystic fibrosis increases the open probability of wild-type and mutant CFTRs.33,34 A similar drug development strategy may be possible to develop activators for mutant ABCD1 given that 30 mutants influence the activity of ABCD1.